ACT Capital Management’s Corvus Pharmaceuticals CRVS Stock Holding History

ACT Capital Management’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$403K	Buy	+27,000	New	+$375K	0.26%	43

Other funds holding CRVS

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Jackson Square Capital San Francisco, California $719M AUM 144.18% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Avity Investment Management Greenwich, Connecticut $1.57B AUM 35.56% 1-Year Est. Return

New York State Common Retirement Fund

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Simon Quick Advisors Morristown, New Jersey $2.48B AUM 21.26% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Pictet Asset Management

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

ACT Capital Management's CRVS Position: Q2 2026 in Review

ACT Capital Management opened a new position in Corvus Pharmaceuticals (CRVS) in Q2 2026: 27,000 shares worth $403K. The stake represents 0.26% of the portfolio and ranks #43 among its holdings.

24 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

ACT Capital Management held 27,000 shares of Corvus Pharmaceuticals worth $403K as of Q2 2026.
Corvus Pharmaceuticals was a new ACT Capital Management position in Q2 2026.
Corvus Pharmaceuticals made up 0.26% of ACT Capital Management's portfolio in Q2 2026, its #43 holding.
24 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on ACT Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.